- Home
- SGLY vs SONN Comparison
SGLY vs SONN Comparison
Compare SGLY & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- SONN
- Stock Information
- Founded
- SGLY 2001
- SONN N/A
- Country
- SGLY United States
- SONN United States
- Employees
- SGLY N/A
- SONN N/A
- Industry
- SGLY
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- SONN Health Care
- Exchange
- SGLY Nasdaq
- SONN Nasdaq
- Market Cap
- SGLY 3.9M
- SONN 3.8M
- IPO Year
- SGLY 2008
- SONN N/A
- Fundamental
- Price
- SGLY $1.02
- SONN $1.13
- Analyst Decision
- SGLY
- SONN Strong Buy
- Analyst Count
- SGLY 0
- SONN 1
- Target Price
- SGLY N/A
- SONN $20.00
- AVG Volume (30 Days)
- SGLY 52.7K
- SONN 44.8K
- Earning Date
- SGLY 08-26-2025
- SONN 08-13-2025
- Dividend Yield
- SGLY N/A
- SONN N/A
- EPS Growth
- SGLY N/A
- SONN N/A
- EPS
- SGLY N/A
- SONN N/A
- Revenue
- SGLY $2,172,036.00
- SONN $1,000,000.00
- Revenue This Year
- SGLY N/A
- SONN $5,376.22
- Revenue Next Year
- SGLY N/A
- SONN N/A
- P/E Ratio
- SGLY N/A
- SONN N/A
- Revenue Growth
- SGLY N/A
- SONN 978.39
- 52 Week Low
- SGLY $0.54
- SONN $1.08
- 52 Week High
- SGLY $7.65
- SONN $10.02
- Technical
- Relative Strength Index (RSI)
- SGLY 51.57
- SONN 41.84
- Support Level
- SGLY $1.02
- SONN $1.10
- Resistance Level
- SGLY $1.16
- SONN $1.17
- Average True Range (ATR)
- SGLY 0.08
- SONN 0.06
- MACD
- SGLY -0.01
- SONN 0.00
- Stochastic Oscillator
- SGLY 50.00
- SONN 13.33
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.